Johnson & Johnson

JNJ

US4781601046

Pharmaceuticals

Market Closed - Nyse Other stock markets 04:00:02 2024-05-28 pm EDT			After market 08:00:00 pm
144.4 ^USD	-1.76%		147.2	+1.93%

May. 28	Sector Update: Health Care Stocks Fall Late Afternoon	MT
May. 28	Sector Update: Health Care Stocks Retreat Tuesday Afternoon	MT

Johnson & Johnson : to Participate in the 2024 RBC Capital Markets Global Healthcare Conference Press Release

May 15, 2024 at 09:36 am EDT

Media contact:	Investor contact:
media-relations@its.jnj.com	investor-relations@its.jnj.com

For immediate release

Johnson & Johnson to Participate in the 2024 RBC Capital Markets Global Healthcare Conference

New Brunswick, N.J., April 4th, 2024 - Johnson & Johnson (NYSE: JNJ) will participate in the 2024 RBC Capital Markets Global Healthcare Conference on Wednesday, May 15th, at the InterContinental Barclay Hotel, New York. Tim Schmid, Executive Vice President, Worldwide Chairman, MedTech, will represent the Company in a session scheduled at 11:00 am (Eastern Time).

This live audio webcast will be available to investors and other interested parties by accessing the Johnson & Johnson website at www.investor.jnj.com.

The audio webcast replay will be available approximately 48-hrs after the webcast.

Attachments

Original Link
Original Document
Permalink

Disclaimer

Johnson & Johnson published this content on 15 May 2024 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 15 May 2024 13:35:14 UTC.

Latest news about Johnson & Johnson

Sector Update: Health Care Stocks Fall Late Afternoon	May. 28	MT
Sector Update: Health Care Stocks Retreat Tuesday Afternoon	May. 28	MT
Sector Update: Health Care	May. 28	MT
Bio-Thera, Stada Enter Deal for Biosimilar Candidate to Johnson & Johnson's Simponi in EU, UK	May. 28	MT
Johnson & Johnson Agrees to Buy Numab Unit, Investigational Skin Disease Treatment For $1.25 Billion	May. 28	MT
Top Midday Stories: Wall Street Returns to T+1 Settlements; T-Mobile Buys US Cellular's Wireless Ops; Energy Transfer Buys WTG Midstream; GameStop Extends Rally	May. 28	MT
Johnson & Johnson to Acquire Experimental Eczema Drug for $1.25 Billion	May. 28	MT
Johnson & Johnson to Acquire Experimental Eczema Drug for $1.25 Billion	May. 28	MT
Johnson & Johnson Acquires Experimental Eczema Drug for $1.25 Billion	May. 28	MT
J&J: acquisition of Swiss eczema biotech company	May. 28	CF
J&J to Acquire Skin Disease Treatment Rights from Numab in $1.25 Billion Deal	May. 28	DJ
J&J acquires rights to skin disorder drug for $1.25 bln	May. 28	RE
J&J: to present advances at ASCO and EHA	May. 24	CF
Some of the biggest splits in Corporate America	May. 23	RE
Cancer victims sue Johnson & Johnson over 'fraudulent' bankruptcies	May. 22	RE
Johnson & Johnson Allegedly Engaged in 'Bad Faith' Bankruptcies That Harm Talc Victims, Lawsuit Says	May. 22	MT
Top Midday Stories: US Targets August 1 Start Date for China Tariff Hikes; CFPB Says BNPL Requires Credit Card-Level Oversight; Target Shares Fall on Earnings Miss; Third BHP Bid Rejected by Anglo American	May. 22	MT
Johnson & Johnson Allegedly Engaged in 'Bad Faith' Bankruptcies That Harm Talc Victims, Lawsuit Says	May. 22	MT
Nanobiotix to Transfer Phase 3 Head and Neck Cancer Study Sponsorship	May. 21	MT
J&J: positive trial for Tremfya in ulcerative colitis	May. 21	CF
Valneva Names New Chief Scientific Officer	May. 21	MT
Global markets live: Apple, Tesla, Pfizer, AstraZeneca, Microsoft...	May. 20
J&J-backed startup Rapport files for US IPO	May. 17	RE
J&J-Linked Rapport Therapeutics Files For IPO	May. 17	DJ
J&J: towards acquisition of Proteologix for $850 million	May. 17	CF

Chart Johnson & Johnson

Duration

Period

More charts

Company Profile

Johnson & Johnson is one of the world's leading producers of healthcare products. Net sales break down by family of products as follows: - pharmaceutical products (55.4%): drugs intended for the treatment of cardiovascular diseases, oncological diseases, gastro-intestinal illnesses, infectious, immunological, neurological, dermatological diseases, etc.; - medical products and equipment (28.9%): diagnostic systems, orthopedic and gynecological equipment, surgical materials, etc. for use by healthcare professionals; - consumer health products (15.7%): OTC drugs (Tylenol, Sudafed, Benadryl, Zyrtec, Motrin, Nicorette and other brands), health and beauty products (Aveeno, Clean & Clear, Dr. CI:Labo, Neutrogena and OGX), baby care products (Johnson's and Aveeno Baby), oral care products (Listerine), feminine hygiene products (Stayfree and Carefree and o.b.), wound care products (Band-Aid and Neosporin) etc. At the end of 2022, Johnson & Johnson has 89 manufacturing facilities located in the United States (28), North America (9), Europe (27), Africa and Asia/Pacific (25). Net sales are distributed geographically as follows: the United States (51.2%), Europe (24.7%), Asia/Pacific and Africa (17.7%) and other (6.4%).

Sector

Pharmaceuticals

Calendar

01:30pm - Bernstein Strategic Decisions Conference

Related indices

Dow Jones Industrial , S&P 500

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

Joseph Wolk, CFO of J&J: End of patent for its flagship drug

January 23, 2024 at 12:30 pm EST

More Strategies

Ratings for Johnson & Johnson

Trading Rating

Investor Rating

ESG Refinitiv

C+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

144.4 USD

Average target price

172.5 USD

Spread / Average Target

+19.49%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
JOHNSON & JOHNSON	-7.89%	347B
ELI LILLY AND COMPANY	+38.59%	727B
MERCK & CO., INC.	+15.66%	319B
ABBVIE INC.	+0.24%	274B
ASTRAZENECA PLC	+13.47%	238B
NOVARTIS AG	+7.35%	204B
ROCHE HOLDING AG	-6.42%	203B
AMGEN INC.	+4.23%	161B
PFIZER, INC.	-1.70%	160B
SANOFI	-1.31%	120B

Other Pharmaceuticals

Johnson & Johnson

Equities

JNJ

US4781601046

Pharmaceuticals

Johnson & Johnson : to Participate in the 2024 RBC Capital Markets Global Healthcare Conference Press Release

EPS Revisions